Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies
Sign Up to like & getrecommendations! Published in 2025 at "Haemophilia"
DOI: 10.1111/hae.70017
Abstract: The Phase 3 studies, XTEND‐1 (NCT04161495) and XTEND‐Kids (NCT04759131), showed once‐weekly efanesoctocog alfa provided high‐sustained factor VIII (FVIII) activity levels that translated into highly effective bleed prevention in patients with severe haemophilia A. read more here.
Keywords: xtend; xtend kids; perioperative management; efanesoctocog alfa ... See more keywords